A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
about
Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells.A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infectionHsp70 enhances presentation of FMDV antigen to bovine CD4+ T cells in vitro.Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategyClearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin.Effect of vaginal immunization with HIVgp140 and HSP70 on HIV-1 replication and innate and T cell adaptive immunity in women.Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.Hsp110-mediated enhancement of CD4+ T cell responses to the envelope glycoprotein of members of the family Flaviviridae in vitro does not occur in vivoIdentification of novel viral receptors with cell line expressing viral receptor-binding protein.Natural anti-CCR5 antibodies in HIV-infection and -exposureIntralymphatic immunotherapyCCR5: From Natural Resistance to a New Anti-HIV Strategy.Inhibition of human immunodeficiency virus type 1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein.The effects of HIV infection on oral mucosal immunity.New routes for allergen immunotherapy.Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs.A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.Assessment of mucosal immunity to HIV-1.The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection.HIV-1 p24-immunoglobulin fusion molecule: a new strategy for plant-based protein production.Development of a human leukocyte antigen-based HIV vaccine.
P2860
Q33214992-7C973778-C2ED-452D-AE26-D6163A2F2787Q33275586-4B96681B-CF09-420D-9BBC-18EC360D30DFQ33683355-240741A6-A92D-4A83-984A-DADE550D2D16Q33701133-EFB397ED-E1DA-4399-AD37-D80684EE7518Q33788768-1C49CADD-2B37-4516-9B1A-8E0AE064160AQ34100215-BFCBC043-2F2B-4EE5-AF25-8AB1EA9E7946Q34261593-658B2CE6-1355-4658-A911-8E0B6EDCF858Q34510719-66B935A8-6FC8-40E0-8C34-09B16D0439F8Q34738862-658B9C82-BE97-4D91-9054-AC52D8B5A2CAQ34990603-D6200ECA-D1AA-43A0-8483-612B7241A933Q35018133-DEB7C7D6-5676-4FA9-9D30-826191FAC806Q35155423-E6B5E6F1-23A4-4943-88B6-1FEC8E6C4D2BQ35260605-FD6156C3-B2B3-4810-ABEF-17B6082B9B48Q35785019-A24B8AEF-CCD3-45C9-874C-E68B65BD3488Q35792444-0BAB36AB-6910-4CDE-A9C8-B60DB8BB8BE2Q36315473-411FE352-4998-4195-97A1-9DDD37AB38D8Q36467653-DFACF3A3-2B75-4D1C-BEFB-D25D4F913DB7Q36864957-6158E1DE-D422-4AD9-B02D-41242949E239Q37461092-9CE969D8-D46E-49FE-B72E-41E507E19CE4Q37535105-C8D2B1DB-5AB3-42A2-A563-33E8DEA9C693Q37547093-0FDD38BC-6D64-4053-A5F9-D9BE362186C1Q37724856-D6B34526-8DDB-40AE-80F8-898DD05C6C20Q47107303-5EC675A5-E113-446F-9781-B2D2C2A454C9Q51092875-9E3BCC96-EDF2-4C2E-959C-1655648D3C03Q55447473-72B2B0ED-3294-4DD1-A608-0E06CE3AE1F8
P2860
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
@en
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
@nl
type
label
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
@en
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
@nl
prefLabel
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
@en
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
@nl
P2093
P1433
P1476
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.
@en
P2093
Charles G Kelly
Herman Oostermeijer
Lesley A Bergmeier
Mahavir Singh
Peter Ten Haaft
Thomas Lehner
Willy M J M Bogers
Yufei Wang
P356
10.1097/00002030-200401020-00003
P407
P577
2004-01-01T00:00:00Z